Research
Hormonal
Tirzepatide (15mg weekly) achieves 20.9% weight loss, with 50-57% of users losing >= 20% body weight, rivaling bariatric surgery.
Tirzepatide 15mg weekly can lead to ~21% weight loss. Over half of users lose 20% or more. This is a powerful option for those with comorbidities.
StrongSupportsVERY_HIGH confidence
The intervention resulted in substantial and dose-dependent reductions in body weight, with mean losses of 15.0%, 19.5%, and 20.9%, respectively... Notably, 50–57% of individuals in the 10 mg and 15 mg groups achieved a weight reduction of 20% or more—an outcome previously attainable primarily through metabolic surgery
Why this rating
Phase 3 RCT data.
Source
Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines
Safi Alqatari et al. · Medicina · 2025
narrative_reviewCited 5×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →